ORPHAN Cures Act

This bill amends a federal drug pricing program to better support manufacturers of drugs for rare diseases. It clarifies that time periods when a drug was designated as an "orphan drug" (for rare diseases) will not count toward the timeline for price negotiations under the program. This change directly affects pharmaceutical companies developing treatments for rare conditions by potentially delaying when their drug prices become subject to federal negotiation. The policy adjustment aims to provide more time for these specialized treatments to reach the market without immediate price constraints.